1 minute reading time (227 words)

Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer With Ritu Salani, MD, MBA, and Floor J. Backes, MD

Cancer of the uterine corpus, also called endometrial cancer (EC), is the most common cancer of the female genital tract, with an estimated 65,950 new cases diagnosed and 12,550 deaths annually in the United States (ACS, 2022). The mortality rate has increased approximately 1% each year from 2015 to 2019, an increase which may be related to a higher rate of advanced-stage cancers, high-risk histologies, and patients being diagnosed at an older age (ACS, 2022). There are significant disparities between White and Black women regarding rates of early-stage diagnosis (75% vs 62%) and 5-year relative survival (84% vs 63%) (ACS, 2022). When patients are diagnosed with distant-stage disease, 5-year relative survival rates plummet to 18% for all races. Early identification of high-risk patients and personalized treatment approaches for this complex, multifaceted disease are needed to improve outcomes. In this activity, Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine, will update learners on the latest research in the pathology, molecular characterization, treatment, and management of endometrial cancer. 

Related Posts

Copyright © Oncology Data Advisor. All rights reserved.